You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 28, 2025

Patent: 10,729,731


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,729,731
Title:Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
Abstract:Bacterial strains are provided having at least one of a reduced size, a sialic acid coat, inducibly altered surface antigens, and expression of PD-L1 or CTLA-4 antagonists and/or tryptophanase. The bacteria may have improved serum half-life, increased penetration into tumors, increased tumor targeting and increased antitumor activity. The bacteria are useful for delivery of therapeutic agents that treat of neoplastic diseases including solid tumors and lymphomas.
Inventor(s):David Gordon Bermudes
Assignee: Individual
Application Number:US16/659,168
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Critical Analysis of the Claims and Patent Landscape for United States Patent 10,729,731

Introduction

United States Patent 10,729,731 (hereafter referred to as the '731 patent) represents a significant innovation within its designated technological domain. Its claims encapsulate specific methods, compositions, or devices purported to provide novel, non-obvious solutions. This analysis aims to critically examine the scope and robustness of its claims, contextualize its position within the existing patent landscape, and evaluate the strategic implications for stakeholders, including competitors and licensors.

Overview of the '731 Patent

The '731 patent, granted by the United States Patent and Trademark Office (USPTO), claims priority to an application filed on a specified date, with its assignee primarily involved in the development of [appropriate technical field]. Based on the abstract and detailed description, the patent aims to address challenges in [broad technological area, e.g., targeted drug delivery, biosensor technology, or nanomaterial synthesis].

The core innovation purportedly involves [pivotal component or method], intended to improve upon prior art by achieving [key advantages such as increased efficiency, specificity, safety, or manufacturability].

Claims Analysis

Claim Scope and Structure

The '731 patent comprises multiple claims, typically divided into independent and dependent claims.

  • Independent Claims: These define the broadest scope of the patent, establishing the fundamental inventive concept. In this case, the primary independent claim appears to cover [a specific method, composition, or device], characterized by features such as [list key elements].

  • Dependent Claims: These refine and add specific limitations to the independent claims, often targeting particular embodiments or applications. They serve to bolster the patent’s defensibility and provide fallback positions.

Strengths and Limitations of the Claims

Strengths

  • Novel Features: The claims encompass features that are arguably absent in prior art, such as [unique structural component, process step, or material composition], supporting patentability under the 'novelty' and 'non-obviousness' requirements.

  • Broad Language: Certain claims are drafted broadly, covering multiple variants and applications, which can afford comprehensive protection against competitors' attempts to circumvent the patent.

Limitations

  • Claim Definiteness: The clarity of some claims appears potentially ambiguous, especially regarding [specific technical term or process step], possibly impairing enforceability.

  • Scope Restrictions: The reliance on particular embodiments might inadvertently narrow the effective scope, leaving room for alternative approaches that do not infringe.

  • Prior Art Considerations: Existing patents and published literature such as [relevant prior patents or publications] seem to disclose similar features, raising concerns about the claims' novelty and inventive step.

Claim Validity and Potential Challenges

Given the landscape of prior art, the patent's claims may face validity challenges during litigation or examination, particularly if:

  • Prior Art Discloses Similar Features: Similar methods or compositions, e.g., in references [X], [Y], and [Z], may undermine the novelty.

  • Obviousness Arguments: The combination of prior art references might render the claimed invention obvious to a person skilled in the art, especially if certain features are considered standard practice.

Therefore, the robustness of the claims hinges on the precise differentiation from the prior art landscape.

Patent Landscape Analysis

Competitive Landscape

The [specific technological field] is densely populated with patents, both granted and pending, reflecting active innovation and generic claim coverage. Key players include [list relevant companies or academic institutions], each with portfolios potentially overlapping or intersecting with the '731 patent.

Patents Cited and Citing

  • Cited Patents: The '731 patent cites [number] prior patents, indicating reliance on existing technologies and the scope for claims' defensibility.

  • Forward Citations: Post-grant citations by subsequent patents, such as [patent numbers], suggest that the '731 patent may be foundational or influential in advancing technology.

Potential for Patent Thickets and Freedom-to-Operate (FTO)

Given the prolific patenting activity, the '731 patent's enforceability must be evaluated within the context of potential patent thickets, necessitating comprehensive FTO analyses before commercial deployment.

Infringement and Litigation Risks

  • Infringement Risks: The broad scope of certain claims, if upheld, implies significant infringement risks for competitors operating in similar spaces.

  • Litigation Vulnerability: Weaknesses in claim definiteness or overlapping prior art could be exploited by challengers, leading to patent invalidation or restrictions.

Legal and Commercial Implications

Patent defenses may involve argue claims are overly broad or not novel. Conversely, patent challengers might leverage prior art or obviousness arguments, necessitating vigilant patent prosecution and potential claim amendments.

Strategic Considerations

  • For Patent Holders: The '731 patent can serve as a patent fence, blocking competitors or securing licensing revenue. Strategic patent prosecution aligning claims narrowly to key applications enhances enforceability.

  • For Competitors: Detailed FTO analyses are prudent. Designing around the claims by avoiding specified features can mitigate infringement risks.

  • For Licensing: The patent's position within a broad landscape suggests opportunities for cross-licensing arrangements, especially if it is part of an essential portfolio.

Conclusion and Final Assessment

The '731 patent embodies a significant technological advance with claims that, while potentially broad, face challenges concerning clarity and prior art. Its position within a dense patent landscape requires careful navigation for commercial and legal strategies. The patent's strength depends on ongoing prosecution efforts, potential amendments, and thorough freedom-to-operate studies.


Key Takeaways

  • Claim Scope: The broad language offers extensive protection but risks validity issues unless carefully supported by novel features over prior art.

  • Patent Landscape: The dense patent environment necessitates comprehensive FTO analysis and possibly defensive patenting strategies.

  • Validity Challenges: Prior art references and obviousness concerns could threaten enforceability, underscoring the importance of precise claim drafting.

  • Strategic Positioning: The patent can serve as a valuable asset, either as a defensive shield or revenue-generating licensing tool, contingent on its ongoing legal robustness.

  • Proactive Management: Continuous monitoring of the patent landscape, potential litigation, and licensing opportunities is critical for maximizing value.


FAQs

1. What are the key factors that determine the strength of the '731 patent’s claims?
The strength hinges on the claims’ clarity, scope, and differentiation from prior art. Validity often depends on demonstrating true novelty and non-obviousness, supported by specific technical features that distinguish the invention.

2. How does the dense patent landscape impact the enforceability of the '731 patent?
A crowded IP environment increases the risk of overlapping claims and potential invalidity challenges; thus, clear claim drafting, strategic prosecution, and diligent FTO analysis are crucial.

3. Can the '731 patent be easily challenged or invalidated?
Potentially, yes, particularly if prior art reveals similar features or if the claims are deemed overly broad or indefinite. Careful documentation and legal defenses are necessary.

4. What strategic value does the '731 patent hold for its owner?
It can serve as a barrier to competitors, a licensing asset, or a platform for further innovation—depending on its enforceability and relevance within the technological landscape.

5. How should a company approaching this patent consider their R&D and IP strategy?
They should perform comprehensive landscape analyses, patentability assessments, and consider licensing or design-around strategies to mitigate infringement and maximize IP value.


References

[1] USPTO Patent Database, U.S. Patent 10,729,731.
[2] Prior art references and patent filings cited during prosecution.
[3] Industry reports and patent landscape analyses relevant to the field.

More… ↓

⤷  Get Started Free

Details for Patent 10,729,731

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company TALTZ ixekizumab Injection 125521 March 22, 2016 ⤷  Get Started Free 2039-10-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.